Guangxiu Dai

机构：Hua Medicine (China)

发表论文 39 篇 · 总被引 942 次 · h-index 9

代表论文

• Discovery of ( S )-1-(1-(Imidazo[1,2- a ]pyridin-6-yl)ethyl)-6-(1-methyl-1 H -pyrazol-4-yl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer (2014 · Journal of Medicinal Chemistry · 被引 135)
• Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ–PI3Kδ Dual Inhibitors (2019 · Journal of Medicinal Chemistry · 被引 36)
• Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor (2023 · Journal of Pharmacology and Experimental Therapeutics · 被引 10)
• Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment (2025 · ACS Medicinal Chemistry Letters · 被引 9)
• Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies (2024 · Frontiers in Pharmacology · 被引 9)
• Bifunctional inhibition of HIV-1 reverse transcriptase: A first step in designing a bifunctional triphosphate (2012 · Bioorganic & Medicinal Chemistry Letters · 被引 7)